Survivin HLA-A2+限制性CTL表位筛选、鉴定及其免疫学效应研究
摘要
【目的】表位是抗原中能被免疫细胞特异性识别的线性片段或空间构象性结构,是引起免疫应答和免疫反应的基本单位,鉴定合适的抗原表位是诱导产生有效肿瘤免疫应答的关键。本研究利用三种计算机算法筛选Survivin抗原HLA-A2+限制性CTL表位;利用不同亲和力的表位肽分别诱导CTL,探讨其免疫学效应和杀瘤特性。
【方法】采用超基序、量化基序法和蛋白酶体裂解法相结合对靶抗原Survivin HLA-A2+限制性CTL表位进行预测筛选;用流式细胞仪检测侯选表位肽与T2细胞结合后荧光强度变化,应用HLA-A2结合实验和流式细胞术检测候选表位肽的结合亲和力,以荧光系数FI(fluorescence index)表示;根据HLA-A2解离实验和流式细胞术检测候选肽的稳定性,以复合物解离50%的时间DC50(dissociation complex 50%)表示。分别用筛选出的高亲和力、中等亲和力及低亲和力表位肽体外诱导CTL并用酶联免疫斑点(ELISPOT)法检测CTL产生分泌IFN-γ的能力;用乳酸脱氢酶(LDH)释放法检测CTL的杀瘤能力。
【结果】1.用超基序法、量化基序法和蛋白酶体裂解法筛选了九条Survivin九肽CTL表位,分别是:20STFKNWPFL28 (SV20-28)、23KNWPFLEGC31 (SV23-31)、96LTLGEFLKL104 (SV96-104)、6LPPAWQPFL14 (SV6-14)、33CTPERMAEA41 (SV33-41)、46CPTENEPDL54 (SV46-54)、130KVRRAIEQL138 (SV130-138)、37RMAEAGFIH45 (SV37-45)、88SVKKQFEEL96 (SV88-96)。2.亲和力分析显示: SV20-28、SV96-104、SV130-138、SV23-31的荧光指数(Fluorescence Index, FI)分别为8.61、6.88、5.89、3.81;SV33-41、SV6-14、SV46-54、SV37-45、SV88-96的FI分别为0.31、-0.29、-0.4、-0.16和-0.03;稳定性分析结果为:SV20-28、SV96-104、SV130-138, DC50( dissociation complex 50)>8h;SV23-31 DC50为4-6h;其余表位肽DC50小于4小时。结果提示:SV20-28、SV96-104、SV130-138为高亲和力表位肽;SV23-31为中等亲和力表位肽;SV33-41、SV6-14、SV46-54、SV37-45、SV88-96为低亲和力表位肽。3.Survivin高亲和性表位SV20-28和中等亲和力表位SV23-31负载DC诱导的CTL能产生分泌IFN-γ细胞,在ELISPOT试验中效靶比为1:1时产生的斑点数分别为183.42±16.07、76.08±8.42,显著高于阴性对照组斑点数,P﹤0.05;而低亲和力表位SV88-96诱导的CTL未能产生明显的IFN-γ分泌细胞。高亲和力及中等亲和力表位肽诱导的CTL能以MHC-I限制方式杀伤Survivin阳性细胞,在效靶比为:50:1、25:1、12.5:1时的杀伤率分别分别为(62.40±5.16)%、(44.0±2.32)%、(26.53±1.07)%和(33.42±4.76)%、(25.16±2.64)%、(15.83±1.57)%,显著高于阴性对照组:(5.59±0.16)%、(4.76.0±0.32)%、(2.93±0.07)%;而低亲和力表位肽SV88-96诱导的免疫细胞对靶细胞没有明显的杀伤作用。
【结论】超基序法、量化基序法和蛋白酶体裂解法相结合可快速有效地预测抗原表位;Survivin表位肽SV20-28、SV23-31可有效诱导CTL产生免疫反应,并能以MHC-I限制方式杀伤Survivin阳性细胞。
【Objective】Epitope can be defined as linear fragment or conformation structure derived from a protein antigen that is recognized by immunocyte and raising immune response.Identification of the appropriate and effective Epitope is essential to develop of efficient protocols for tumor immuno response. We use three computer algorithms to screen and identify of HLA-A2+ -restricted survivin-derived CTL epotide and evaluate the immune response and test the ability of CTL generated in vitro with different kinds of survivin-derived peptide.【Methods】HLA-A2+ -restricted survivin-derived CTL epotides were predicted by using a combination of three computer algorithms that is supermotif, quantitative motif and proteasomal cleavages methods. The binding capacity and complex stability of candidate epitope peptides were measured by using flowcytometry.【Results】We have screened and identified of nine HLA-A2 survivin nonamers that is 20STFKNWPFL28(SV20-28)、23KNWPFLEGC31(SV23-31)、96LTLGEFLKL104 (SV96-104)、6LPPAWQPFL14(SV6-14)、33CTPERMAEA41(SV33-41)、46CPTENEPDL54(SV46-54)、130KVRRAIEQL138(SV130-138)、37RMAEAGFIH45(SV37-45)、88SVKKQFEEL96(SV88-96);The binding affinity analysis showed that candidate peptides SV20-28、SV96-104、SV130-138 and SV23-31 have the fluoresence index(FI) of 8.61、6.88、5.89、3.81 respectively, peptides SV33-41、SV6-14、SV46-54、SV37-45 and SV88-96 have the FI 0.31、-0.29、-0.4、-0.16 and -0.03 respectively. The peptide/HLA-A2 complexes stablity assay indicated that the dissociation complex 50(DC50) for peptides SV20-28、SV96-104、SV130-138 were longer than 8h,for SV23-31 was 4-6h and for the rest candidate peptides were less than 4h. Based on their ability to binding to HLA-A2 and to form stable peptide/HLA-A2 complexes, we separated nine candidate survivin peptides into three groups: High-affinity peptide: SV20-28、SV96-104、SV130-138 ; Intermediate-affinity peptide: SV23-31and Low-affinity peptide: SV33-41、SV6-14、SV46-54、SV37-45、SV88-96. Survivin-specific CTL could be generated from high-affinity and intermediate-affinity survivin peptide SV20-28 and SV23-31 loaded dendritic cell and secreted IFN-γ-producing cells. The number of the spots for CTL/SV20-28 cell and CTL/SV23-31 cell was 183.42±16.07 and 76.08±8.42 respectively which is markedly higher than that of negative control with P﹤0.05. While no obvious immuno-responses was observed for CTL/SV88-96 cell; Survivin-specific CTL induced from high-affinity and intermediate-affinity survivin peptide SV20-28 and SV23-31 can kill survivin positive cancer cells in MHC class I-restricted fashion. The specific lysis rate for CTL/SV20-28 and CTL/SV23-31 were (62.40±5.16)%,(44.0±2.32)%,(26.53±1.07)% and (33.42±4.76)%,(25.16±2.64)%,(15.83±1.57)% respectively with the effector to targe was 50 to1,25 to1 and 12.5 to1.
【Conclusions】Antigen epitope could be quickly and efficiently predicted by using supermotif、quantitative motif and proteasomal cleavages methods. Survivin-derived peptides SV20-28 and SV23-31 can efficiently induce survivin-specific CTLs which can recongnize and kill survivin positive cancer cells in MHC class I-restricted fashion.
【方法】采用超基序、量化基序法和蛋白酶体裂解法相结合对靶抗原Survivin HLA-A2+限制性CTL表位进行预测筛选;用流式细胞仪检测侯选表位肽与T2细胞结合后荧光强度变化,应用HLA-A2结合实验和流式细胞术检测候选表位肽的结合亲和力,以荧光系数FI(fluorescence index)表示;根据HLA-A2解离实验和流式细胞术检测候选肽的稳定性,以复合物解离50%的时间DC50(dissociation complex 50%)表示。分别用筛选出的高亲和力、中等亲和力及低亲和力表位肽体外诱导CTL并用酶联免疫斑点(ELISPOT)法检测CTL产生分泌IFN-γ的能力;用乳酸脱氢酶(LDH)释放法检测CTL的杀瘤能力。
【结果】1.用超基序法、量化基序法和蛋白酶体裂解法筛选了九条Survivin九肽CTL表位,分别是:20STFKNWPFL28 (SV20-28)、23KNWPFLEGC31 (SV23-31)、96LTLGEFLKL104 (SV96-104)、6LPPAWQPFL14 (SV6-14)、33CTPERMAEA41 (SV33-41)、46CPTENEPDL54 (SV46-54)、130KVRRAIEQL138 (SV130-138)、37RMAEAGFIH45 (SV37-45)、88SVKKQFEEL96 (SV88-96)。2.亲和力分析显示: SV20-28、SV96-104、SV130-138、SV23-31的荧光指数(Fluorescence Index, FI)分别为8.61、6.88、5.89、3.81;SV33-41、SV6-14、SV46-54、SV37-45、SV88-96的FI分别为0.31、-0.29、-0.4、-0.16和-0.03;稳定性分析结果为:SV20-28、SV96-104、SV130-138, DC50( dissociation complex 50)>8h;SV23-31 DC50为4-6h;其余表位肽DC50小于4小时。结果提示:SV20-28、SV96-104、SV130-138为高亲和力表位肽;SV23-31为中等亲和力表位肽;SV33-41、SV6-14、SV46-54、SV37-45、SV88-96为低亲和力表位肽。3.Survivin高亲和性表位SV20-28和中等亲和力表位SV23-31负载DC诱导的CTL能产生分泌IFN-γ细胞,在ELISPOT试验中效靶比为1:1时产生的斑点数分别为183.42±16.07、76.08±8.42,显著高于阴性对照组斑点数,P﹤0.05;而低亲和力表位SV88-96诱导的CTL未能产生明显的IFN-γ分泌细胞。高亲和力及中等亲和力表位肽诱导的CTL能以MHC-I限制方式杀伤Survivin阳性细胞,在效靶比为:50:1、25:1、12.5:1时的杀伤率分别分别为(62.40±5.16)%、(44.0±2.32)%、(26.53±1.07)%和(33.42±4.76)%、(25.16±2.64)%、(15.83±1.57)%,显著高于阴性对照组:(5.59±0.16)%、(4.76.0±0.32)%、(2.93±0.07)%;而低亲和力表位肽SV88-96诱导的免疫细胞对靶细胞没有明显的杀伤作用。
【结论】超基序法、量化基序法和蛋白酶体裂解法相结合可快速有效地预测抗原表位;Survivin表位肽SV20-28、SV23-31可有效诱导CTL产生免疫反应,并能以MHC-I限制方式杀伤Survivin阳性细胞。
【Objective】Epitope can be defined as linear fragment or conformation structure derived from a protein antigen that is recognized by immunocyte and raising immune response.Identification of the appropriate and effective Epitope is essential to develop of efficient protocols for tumor immuno response. We use three computer algorithms to screen and identify of HLA-A2+ -restricted survivin-derived CTL epotide and evaluate the immune response and test the ability of CTL generated in vitro with different kinds of survivin-derived peptide.【Methods】HLA-A2+ -restricted survivin-derived CTL epotides were predicted by using a combination of three computer algorithms that is supermotif, quantitative motif and proteasomal cleavages methods. The binding capacity and complex stability of candidate epitope peptides were measured by using flowcytometry.【Results】We have screened and identified of nine HLA-A2 survivin nonamers that is 20STFKNWPFL28(SV20-28)、23KNWPFLEGC31(SV23-31)、96LTLGEFLKL104 (SV96-104)、6LPPAWQPFL14(SV6-14)、33CTPERMAEA41(SV33-41)、46CPTENEPDL54(SV46-54)、130KVRRAIEQL138(SV130-138)、37RMAEAGFIH45(SV37-45)、88SVKKQFEEL96(SV88-96);The binding affinity analysis showed that candidate peptides SV20-28、SV96-104、SV130-138 and SV23-31 have the fluoresence index(FI) of 8.61、6.88、5.89、3.81 respectively, peptides SV33-41、SV6-14、SV46-54、SV37-45 and SV88-96 have the FI 0.31、-0.29、-0.4、-0.16 and -0.03 respectively. The peptide/HLA-A2 complexes stablity assay indicated that the dissociation complex 50(DC50) for peptides SV20-28、SV96-104、SV130-138 were longer than 8h,for SV23-31 was 4-6h and for the rest candidate peptides were less than 4h. Based on their ability to binding to HLA-A2 and to form stable peptide/HLA-A2 complexes, we separated nine candidate survivin peptides into three groups: High-affinity peptide: SV20-28、SV96-104、SV130-138 ; Intermediate-affinity peptide: SV23-31and Low-affinity peptide: SV33-41、SV6-14、SV46-54、SV37-45、SV88-96. Survivin-specific CTL could be generated from high-affinity and intermediate-affinity survivin peptide SV20-28 and SV23-31 loaded dendritic cell and secreted IFN-γ-producing cells. The number of the spots for CTL/SV20-28 cell and CTL/SV23-31 cell was 183.42±16.07 and 76.08±8.42 respectively which is markedly higher than that of negative control with P﹤0.05. While no obvious immuno-responses was observed for CTL/SV88-96 cell; Survivin-specific CTL induced from high-affinity and intermediate-affinity survivin peptide SV20-28 and SV23-31 can kill survivin positive cancer cells in MHC class I-restricted fashion. The specific lysis rate for CTL/SV20-28 and CTL/SV23-31 were (62.40±5.16)%,(44.0±2.32)%,(26.53±1.07)% and (33.42±4.76)%,(25.16±2.64)%,(15.83±1.57)% respectively with the effector to targe was 50 to1,25 to1 and 12.5 to1.
【Conclusions】Antigen epitope could be quickly and efficiently predicted by using supermotif、quantitative motif and proteasomal cleavages methods. Survivin-derived peptides SV20-28 and SV23-31 can efficiently induce survivin-specific CTLs which can recongnize and kill survivin positive cancer cells in MHC class I-restricted fashion.
引文
1. JH Kessler and CJM Melief. Identification of T-cell epotopes for cancer immunotherapy. [J] Leukemia, 2007; 21: 1859-1874。
2. G Ambrosini, C Adida, DC Altieri. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.[J] Nat Med. 1997; 3 :917-21.
3. S.M. Allen, S.R. Florell, A.N. Hanks, et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression, Cancer Res.2003; 63: 567–572.
4. N.S. Williams, R.B. Gaynor, S. Scoggin, et al. Identication and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. [J] Clin. Cancer Res.2003; 9: 931–946.
5. S Reker, A Meier, L Holten-Andersen, et al. Identification of novel survivin-derived CTL epitopes. [J] Cancer Biol Ther, 2004;3:173– 179.
6. MH Andersen, LO Pedersen, B Capeller, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. [J] Cancer Res, 2001;61: 5964-5968.
7. Y Hirohashi, T Torigoe, A Maeda, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. [J] Clin Cancer Res, 2002;8:1731-1739.
8. F. Li. Survivin study: what is the next wave?, [J] Cell Physiol. 2003;197: 8–29。
9. JH Kessler and CJM Melief. Identification of T-cell epitopes for cancer immunotherapy.[J] Leukemia, 2007; 21, 1859–1874。
10. HG Rammensee,T Friede, S Strevanoviic, et al. MHC ligands and peptide motifs:first listing. [J] Immunogenetic,1995; 41:178-183。
11. J Sidney, HN Grey, RT Kub, et al.Practical,bioche-mical and evolutinary implications of the discovery of HLA class I supermotifs.[J] Immunol Today,1996;17:261-267。
12. P Cascio, C Hilton, A F Kisselev, et al. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. [J ] EMBO J , 2001 ; 20 (10) : 2357-2362.
13. B Minev, J Hipp, F H irat, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(9):4796-4801
14. T Sophie, S Antonio, S Eleanna, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. [J] Eur. J. Immunol. 2000; 30: 3411–3421.
15. D. C Altieri, et al. Validating survivin as a cancer therapeutic target. [J] Nature Rev. Cancer , 2003;3, 46–54.
16. MM Bachinsky, DE Guillen, SR Patel,et al. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. [J] Cancer Immun, 2005; 5:6-14
17. M Bhasin, GP Raghava, et al. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. [ J ] J Biosci , 2007; 32 (1) : 31-38.
18. P Steve,S Markus,G Brigitte,et al. A MAGE-A1 HLA-A*0201 Epitope Identified by Mass Spectrometry. [J] Cancer Res, 2001; 61: 4072–4077.
19.朱焱等。乙肝病毒X蛋白HLA-A0201限制性CTL表位的筛选与鉴定。第二军医大学学报,2007;28(11):1169-1174.
20. M H Andersen, L Tan, I Sndergaard, et al . Poor correspondence between predicted and experimental binding of peptides to classⅠMHC molecules [J ] Tissue Antigens ,2000;55 :519-531.
21. H W Nijman, J G Houbiers, M P Vierboom, et al. Identification of peptide sequences that potentially trigger HLA-A2.1 restricted cytotoxic T lymphocytes [J ] Eur J Immunol, 1993; 23 (6) : 1215.
22. A W. Purcell, J McCluskey and J Rossjohn. More than one reason to rethink the use of peptides in vaccine design. [J] Nature, 2007; 6:404-414
23.陈明水,陈强,李洁羽,等。Survivin HLA-A2高亲和性CTL表位预测及鉴定。中国肿瘤生物治疗杂志, 2009; 16(3):1-5
24. S.M. Allen, S.R. Florell, A.N. Hanks, et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression,[J] Cancer Res, 2003; 63: 567–572.
25. N.S. Williams, R.B. Gaynor, S. Scoggin, et al. Identication and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. [J] Clin Cancer Res, 2003; 9: 931–946.
26. V.E. Velculescu, S.L. Madden, L. Zhang,et al. Analysis of human transcriptomes. [J] Nat Genet, 1999; 23: 387–388.
27.应学翔,邹强,徐永华,等。负载Her-2多肽的DCIK细胞对乳腺癌细胞杀伤作用研究,分子细胞生物学报, 2007; 40(4):193-197.
28. K.Kono, A Takahashi, H Sugai, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.[J] Clin Cancer Res, 2002; 8: 3394-400.
29. M Schmitz, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. [J] Cancer Res, 2000; 60: 4845–4849.
30. G. Preta, D. Marescotti, C. Fortini, et al. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells. [J] Scandinavian Journal of Immunology, 2008; 68: 579-588
31. M H Andersen, L ?. Pedersen, B Capeller,et al. Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients. [J] Cancer Research, 2001; 61: 5964–5968.
32. V Pisarev, et al. Full-length dominant-negative survivin for cancer immunotherapy. [J] Clin. Cancer Res. 2003;9: 6523–6533.
33.J Arai, M Yasukawa, H Ohminami ,et al . Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes .[ J ] Blood , 2001; 97 :2903.
1. A Suzuki, M Hayashida, T Ito, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. [J] Oncogene, 2000, 19(29): 3225-3234.
2. V.E. Velculescu, S.L. Madden, L. Zhang,et al. Analysis of human transcriptomes. [J] Nat Genet, 1999, 23: 387–388.
3. J Michael, Duffy, O’D Norma, J Donal, et al. Survivin: A promising tumor biomarker. [J] Cancer Letters, 2007, 249: 49-60.
4. C.Mahotka, M.Wenzel, E.Springer, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with di.erent antiapoptotic properties. [J] Cancer Res, 1999, 59: 6097–6102.
5. A. Badran, A. Yoshida, K. Ishikawa, et al. Identication of a novel splice variant of the human anti-apoptosis gene survivin, Biochem. [J] Biophys Res Commun, 2004, 314: 902-907.
6. H. Caldas, L.E. Honsey, R.A. Altura, et al. Survivin 2a: a novel survivin splice variant expressed in human malignancies. [J] Mol Cancer, 2005, 4: 11-17.
7. DC Altieri. The molecular basis and potential role of survivin in cancer diagnosis and therapy. [J]Trends Mol Med, 2001, 7(12): 542-547.
8. M Schmitz, P Diestelkoetter, B Weigle, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. [J] Cancer Res, 2000, 60:4845-4849.
9. S Reker, A Meier, L Holten-Andersen, et al. Identification of novel survivin-derived CTL epitopes. [J] Cancer Biol Ther, 2004, 3:173-179.
10. P Matthias, H York, Z Florian, et al. Identification of a promiscuous HLA DR–restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. [J] Human Immunology ,2007, 68:572-576.
11. H Sjoerd, B Var der, JW Marjan,et a1.Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. [J] Immunol, 1996, 156: 3308-3314.
12. K Falk, O.Ro¨tzschke, S.Stevanovic, et al . Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. [J] Nature, 1991, 351:290-296..
13 H. G Rammensee, T. Friede, and S. Stevanovic. MHC ligands and peptide motifs: first listing. [J] Immunogenetics, 1995, 41(4):178-186.
14. M HAndersen, L ? Pedersen, J C Becker, et al. Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients. [J] Cancer Res, 2000, 61(3):869-872.
15. K Otto, M H Andersen, A Eggert, et al. Lack of toxicity of therapy induced T cell responses against the universal tumour antigen surviving. [J] Vaccine, 2005; 23(7):884-889.
16. T Tsuruma, F Hata, T Torigoe, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. [J] Journal of Translational Medicine, 2004;2(19):
17. C Casati, P Dalerba, L Rivoltini, et al . The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. [J] Cancer Res, 2003; 63(15):4507-4515.
2. G Ambrosini, C Adida, DC Altieri. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.[J] Nat Med. 1997; 3 :917-21.
3. S.M. Allen, S.R. Florell, A.N. Hanks, et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression, Cancer Res.2003; 63: 567–572.
4. N.S. Williams, R.B. Gaynor, S. Scoggin, et al. Identication and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. [J] Clin. Cancer Res.2003; 9: 931–946.
5. S Reker, A Meier, L Holten-Andersen, et al. Identification of novel survivin-derived CTL epitopes. [J] Cancer Biol Ther, 2004;3:173– 179.
6. MH Andersen, LO Pedersen, B Capeller, et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. [J] Cancer Res, 2001;61: 5964-5968.
7. Y Hirohashi, T Torigoe, A Maeda, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. [J] Clin Cancer Res, 2002;8:1731-1739.
8. F. Li. Survivin study: what is the next wave?, [J] Cell Physiol. 2003;197: 8–29。
9. JH Kessler and CJM Melief. Identification of T-cell epitopes for cancer immunotherapy.[J] Leukemia, 2007; 21, 1859–1874。
10. HG Rammensee,T Friede, S Strevanoviic, et al. MHC ligands and peptide motifs:first listing. [J] Immunogenetic,1995; 41:178-183。
11. J Sidney, HN Grey, RT Kub, et al.Practical,bioche-mical and evolutinary implications of the discovery of HLA class I supermotifs.[J] Immunol Today,1996;17:261-267。
12. P Cascio, C Hilton, A F Kisselev, et al. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. [J ] EMBO J , 2001 ; 20 (10) : 2357-2362.
13. B Minev, J Hipp, F H irat, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(9):4796-4801
14. T Sophie, S Antonio, S Eleanna, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. [J] Eur. J. Immunol. 2000; 30: 3411–3421.
15. D. C Altieri, et al. Validating survivin as a cancer therapeutic target. [J] Nature Rev. Cancer , 2003;3, 46–54.
16. MM Bachinsky, DE Guillen, SR Patel,et al. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. [J] Cancer Immun, 2005; 5:6-14
17. M Bhasin, GP Raghava, et al. A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. [ J ] J Biosci , 2007; 32 (1) : 31-38.
18. P Steve,S Markus,G Brigitte,et al. A MAGE-A1 HLA-A*0201 Epitope Identified by Mass Spectrometry. [J] Cancer Res, 2001; 61: 4072–4077.
19.朱焱等。乙肝病毒X蛋白HLA-A0201限制性CTL表位的筛选与鉴定。第二军医大学学报,2007;28(11):1169-1174.
20. M H Andersen, L Tan, I Sndergaard, et al . Poor correspondence between predicted and experimental binding of peptides to classⅠMHC molecules [J ] Tissue Antigens ,2000;55 :519-531.
21. H W Nijman, J G Houbiers, M P Vierboom, et al. Identification of peptide sequences that potentially trigger HLA-A2.1 restricted cytotoxic T lymphocytes [J ] Eur J Immunol, 1993; 23 (6) : 1215.
22. A W. Purcell, J McCluskey and J Rossjohn. More than one reason to rethink the use of peptides in vaccine design. [J] Nature, 2007; 6:404-414
23.陈明水,陈强,李洁羽,等。Survivin HLA-A2高亲和性CTL表位预测及鉴定。中国肿瘤生物治疗杂志, 2009; 16(3):1-5
24. S.M. Allen, S.R. Florell, A.N. Hanks, et al. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression,[J] Cancer Res, 2003; 63: 567–572.
25. N.S. Williams, R.B. Gaynor, S. Scoggin, et al. Identication and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. [J] Clin Cancer Res, 2003; 9: 931–946.
26. V.E. Velculescu, S.L. Madden, L. Zhang,et al. Analysis of human transcriptomes. [J] Nat Genet, 1999; 23: 387–388.
27.应学翔,邹强,徐永华,等。负载Her-2多肽的DCIK细胞对乳腺癌细胞杀伤作用研究,分子细胞生物学报, 2007; 40(4):193-197.
28. K.Kono, A Takahashi, H Sugai, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.[J] Clin Cancer Res, 2002; 8: 3394-400.
29. M Schmitz, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. [J] Cancer Res, 2000; 60: 4845–4849.
30. G. Preta, D. Marescotti, C. Fortini, et al. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells. [J] Scandinavian Journal of Immunology, 2008; 68: 579-588
31. M H Andersen, L ?. Pedersen, B Capeller,et al. Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients. [J] Cancer Research, 2001; 61: 5964–5968.
32. V Pisarev, et al. Full-length dominant-negative survivin for cancer immunotherapy. [J] Clin. Cancer Res. 2003;9: 6523–6533.
33.J Arai, M Yasukawa, H Ohminami ,et al . Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes .[ J ] Blood , 2001; 97 :2903.
1. A Suzuki, M Hayashida, T Ito, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. [J] Oncogene, 2000, 19(29): 3225-3234.
2. V.E. Velculescu, S.L. Madden, L. Zhang,et al. Analysis of human transcriptomes. [J] Nat Genet, 1999, 23: 387–388.
3. J Michael, Duffy, O’D Norma, J Donal, et al. Survivin: A promising tumor biomarker. [J] Cancer Letters, 2007, 249: 49-60.
4. C.Mahotka, M.Wenzel, E.Springer, et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with di.erent antiapoptotic properties. [J] Cancer Res, 1999, 59: 6097–6102.
5. A. Badran, A. Yoshida, K. Ishikawa, et al. Identication of a novel splice variant of the human anti-apoptosis gene survivin, Biochem. [J] Biophys Res Commun, 2004, 314: 902-907.
6. H. Caldas, L.E. Honsey, R.A. Altura, et al. Survivin 2a: a novel survivin splice variant expressed in human malignancies. [J] Mol Cancer, 2005, 4: 11-17.
7. DC Altieri. The molecular basis and potential role of survivin in cancer diagnosis and therapy. [J]Trends Mol Med, 2001, 7(12): 542-547.
8. M Schmitz, P Diestelkoetter, B Weigle, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. [J] Cancer Res, 2000, 60:4845-4849.
9. S Reker, A Meier, L Holten-Andersen, et al. Identification of novel survivin-derived CTL epitopes. [J] Cancer Biol Ther, 2004, 3:173-179.
10. P Matthias, H York, Z Florian, et al. Identification of a promiscuous HLA DR–restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. [J] Human Immunology ,2007, 68:572-576.
11. H Sjoerd, B Var der, JW Marjan,et a1.Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. [J] Immunol, 1996, 156: 3308-3314.
12. K Falk, O.Ro¨tzschke, S.Stevanovic, et al . Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. [J] Nature, 1991, 351:290-296..
13 H. G Rammensee, T. Friede, and S. Stevanovic. MHC ligands and peptide motifs: first listing. [J] Immunogenetics, 1995, 41(4):178-186.
14. M HAndersen, L ? Pedersen, J C Becker, et al. Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients. [J] Cancer Res, 2000, 61(3):869-872.
15. K Otto, M H Andersen, A Eggert, et al. Lack of toxicity of therapy induced T cell responses against the universal tumour antigen surviving. [J] Vaccine, 2005; 23(7):884-889.
16. T Tsuruma, F Hata, T Torigoe, et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. [J] Journal of Translational Medicine, 2004;2(19):
17. C Casati, P Dalerba, L Rivoltini, et al . The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. [J] Cancer Res, 2003; 63(15):4507-4515.